evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

197 questions · 197 findings · 34 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 83 · 42.1%GRADE not reported 0 · 0%Very low 41 · 20.8%Low 38 · 19.3%Moderate 31 · 15.7%High 4 · 2%

Summary of findings for combination antimicrobial susceptibility testing vs conventional treatment (separate testing)

Lung function(FEV1 or FVC L/min or % predicted) · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings for combination antimicrobial susceptibility testing vs conventional treatment (separate testing)

Length of hospital stay · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings for combination antimicrobial susceptibility testing vs conventional treatment (separate testing)

Sputum bacterial density (CFU/mL) · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings for combination antimicrobial susceptibility testing vs conventional treatment (separate testing)

All‐cause mortality · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings: Inhaled antibiotics vs IV antibiotics

Need for additional IV or oral antibiotics · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

It is very uncertain whether summary of findings: Inhaled antibiotics changes need for additional IV or oral antibiotics compared with IV antibiotics (very low certainty).

1 finding from 1 review

Summary of findings: monoclonal antibody KB001‐A vs placebo

Respiratory function number of episodes of a drop in FEV1 (unit of measurement not given) · children (12 or over) and adults with cystic fibrosis and lung infection

It is very uncertain whether summary of findings: monoclonal antibody KB001‐A changes respiratory function number of episodes of a drop in FEV1 (unit of… compared with placebo (very low certainty).

1 finding from 1 review

Summary of findings: monoclonal antibody KB001‐A vs placebo

Number experiencing adverse effects · children (12 or over) and adults with cystic fibrosis and lung infection

It is very uncertain whether summary of findings: monoclonal antibody KB001‐A changes adverse events number of participants experiencing adverse events compared with placebo (very low certainty).

1 finding from 1 review

Summary of findings: monoclonal antibody KB001‐A vs placebo

Need for antibiotics time to need for antibiotics · children (12 or over) and adults with cystic fibrosis and lung infection

Summary of findings: monoclonal antibody KB001‐A showed no clear difference in need for antibiotics time to need for antibiotics compared with placebo (moderate certainty).

1 finding from 1 review